Neuralstem's NSI-189 misses in Phase II for MDD

Neuralstem Inc. (NASDAQ:CUR) reported top-line data from a Phase II trial in 220 patients with major depressive disorder (MDD) showing that once- and twice-daily 40 mg doses of NSI-189 each missed the primary endpoint of improving Montgomery-Asberg Depression Rating Scale (MADRS) score from baseline to week 12 vs. placebo. Once-daily NSI-189 did meet the secondary endpoint of improving patient-rated Symptoms of Depression Questionnaire (SDQ) score vs. placebo (p=0.044). NSI-189 was well tolerated with no serious adverse events reported.

Other secondary endpoints in the double-blind, U.S. trial include the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH CPFQ) and the 17-item Hamilton Depression Rating Scale (HAMD-17)...